European Stocks Subdued as HSBC and Novo Nordisk Lead Declines https://t.co/vMxMEjLklZ ...

More than a third of PTSD patients who took a cannabis-derived drug stopped having nightmares altogether, a new study from researchers in Germany found. Read more: https://t.co/3YwewhQlp2📸: Picture Alliance via Getty Images https://t.co/WMkGMSi9lh ...

Breaking news tonight. Another popular food chain now pulling produce over concerns of salmonella. TMEX chain Quudoba removing jalapenños just hours after Chipotle took similar action.The case is now expanding to even more states. We'll tell you where. Plus, the popular vacation destination sounding the alarm over a stomach parasite possibly linked to lettuce.New details on the security threat at President Trump's golf club ahead of his visit, the guns they found, and what we're learning about the close cal ...

On today’s Big Take podcast, the $19 billion market for menopause treatment is booming. But is it leaving some women behind? @kristenvbrown explains.🎙️ Listen now: https://t.co/CDKZEjxWqv https://t.co/vNH0s1qaFA ...

Bayer’s Monsanto and plaintiff attorneys asked to postpone a hearing where a Missouri judge will weigh whether to approve a $7.25 billion settlement of thousands of US lawsuits alleging Roundup weedkiller caused cancer https://t.co/AbBAbhjOep ...

The $19 billion market for menopause treatment is booming. But the gold rush is leaving some women behind. https://t.co/0mq8v3MwUr https://t.co/Tc8jQqUKQN ...

LIVE FROM BLOOMBERG’S WORLD HEADQUARTERS IN NEW YORK CITY. WE ARE TRACKING THE KEY PLAYERS, THE MAJOR MOVES, AND THE CAPITAL FLOWS SHAPING MARKETS, THIS IS "BLOOMBERG DEALS." >> WELCOME TO ANOTHER EPISODE OF "BLOOMBERG DEALS," THE ONLY SHOW DEDICATED TO CORPORATE ACTION SHAPING MARKETS. POLYMARKET SEEKS ANOTHER RAISE.IT COULD BE THE LARGEST PHARMA DEAL EVER, BUT INVESTORS ARE THROWING COLD WATER ON IT. ASTRAZENECA. WE WILL SPEAK WITH THE CEO OF STAR BOARD WHO HAS SEVERAL ACTIVIST CAMPAIGNS UNDERWAY.LET'S GE ...

Back to all time high as it is 30 minutes ago until the start of trading. I'm Dani Burger and I'm Michael McKee. Bloomberg.Open interest starts right now. Coming up on the show, the S&P extends its winning streak even as sky high eye spending since space Ken Griffin Citadel is already cashing in on its bargain bet on situational awareness and Wall Street banker bonuses are set to climb yet again as volatile markets boost profits. Speaking of those volatile markets, let's look at space now.It is down 11.3% i ...

The company smashed estimates for the quarter and hiked its revenue outlook once again. It now expects sales of 85 billion to 87 billion, up from a previous outlook of 82 billion to 85 billion. Sales jumped 48% this quarter thanks to higher demand for Zepbound and Munjaro, which helped offset those lower prices of those treatments in the US.And Munjara almost topped 10 billion in sales for the first time. And we're seeing strong demand for that drug internationally. One thing I'll highlight is that this is ...

And I think the best news here about the oral category is it's really expansionary. It's not cannibalizing Zepbound. In fact, Zepbound actually accelerated during these oral launches uh with new starts and our and our market share there.So, um I think the big concern last year from the street was how much growth could there be. Uh is this just a business where people going to cycle on and off the therapies. Is it limited by insurance.I think what we're seeing in the first half of this year and with Lily's r ...